Lazard Asset Management
FBIO icon

Lazard Asset Management’s Fortress Biotech FBIO Stock Holding History

Lazard Asset Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-328
Closed -$6K – 2441
2022
Q1 		$6K Sell
328
-1,181
-78% -$32.3K ﹤0.01% 2169
2021
Q4 		$56K Buy
+1,509
New +$67.3K ﹤0.01% 1687

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Lazard Asset Management's FBIO Position: Q2 2022 in Review

Lazard Asset Management sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 328 shares — an estimated $6K sold.

Lazard Asset Management first reported a position in FBIO in Q4 2021 and held it in 2 quarters. The position peaked at $56K in Q4 2021. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

  • Lazard Asset Management reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
  • Lazard Asset Management sold 328 Fortress Biotech shares in Q2 2022, an estimated $6K.
  • Lazard Asset Management first reported a position in Fortress Biotech in Q4 2021 and held it in 2 quarters.
  • Lazard Asset Management's Fortress Biotech position peaked at $56K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on Lazard Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.